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A roadmap for 
Glycoscience in Europe
Glycoscience is the science and technology of carbohydrates, 
which are the most abundant biological molecules on Earth and 
make up part of the biology of all living organisms. Glycoscience is 
recognised worldwide as an emerging area with the potential for 
radically new biotechnological applications to solve several of the 
challenges faced by modern society. 
We see a number of exciting opportunities which are of great 
interest to European Society and Bioindustries, in particular in the 
areas of Pharmaceuticals and Personalised Medicine (addressing 
challenges in health), Food (food security, wellbeing) and 
Biomaterials (resource efficiency and raw materials). Underpinning 
these opportunities will be a number of emerging Glycoscience 
Tools, particularly in synthesis, analysis, bioinformatics and 
modelling, which will open up glycosciences to a much wider 
scientific and industrial community and overcome barriers to 
entry for commercial applications. Importantly, full exploitation 
will only be possible, if the broader community is educated in 
the opportunities brought by the emerging field of glycoscience, 
through cooperation with the media and policy makers, as well as 
Education and Training for students and scientists at all levels.
The European Glycosciences Forum (EGSF) has brought together 
a group of European experts to consider how the recent leading 
achievements of glycoscience and glycotechnology in Europe can be 
driven forward.  This paper summarises highlights and achievements 
of scientific and technological excellence and puts forward a number 
of areas where some of the most promising opportunities for 
translation into products on the European market have been identified. 
Glycoscience is becoming an essential part of modern innovative 
biotechnology and having access to state-of-the-art knowledge and 
technologies in glycoscience will provide the European bio-based 
industries with a strong competitive advantage on a worldwide stage 
leading to long-term job creation and sustainability. However, our 
goals will be slow to achieve with the current fragmented landscape 
of national centres and short-term projects. To take full advantage 
of the opportunities presented by glycoscience, we recommend 
the establishment of an Integrated European Roadmap for 
Glycobiotechnology with the aim of setting up a number of 
transnational long-term public-private partnerships. 
EGSF Chair: Professor Sabine Flitsch (UK)
EGSF Vice Chair: Professor Serge Perez (France)
Carbohydrates are produced from sunlight and carbon dioxide 
by plants, algae and some photosynthetic bacteria. Created by 
photosynthesis, carbohydrates provide the largest renewable 
biomass on Earth and are the economically viable and sustainable 
alternative to fossil resources for energy and raw materials. 
Carbohydrates are the biomass that helps reduce carbon footprints 
and thus allowing the European Bioeconomy to achieve economic 
growth without damage to the environment.
During the dynamic process of glycosylation, the simple 
carbohydrates from photosynthesis are converted to complex 
carbohydrates, glycoconjugates or glycans which are an integral 
part of cell biology, and are present on the cell surface and the 
macromolecules contained within. Glycosylation influences the 
function of these molecules, playing an essential role in health 
and disease. This includes the development of innate and adaptive 
immunity, the growth and spread of cancer, responses to bacterial 
and viral infections, and the development of diseases such as 
diabetes. Understanding and exploiting glycoscience and glycomics 
has become an essential part of modern molecular medicine.
How can glycoscience benefit Society and drive the Bioeconomy?
What is 
glycoscience?
The publication 
output of European 
R&D glycoscientists 
is the highest in the 
world. The size of the 
circles represents the 
relative proportion of 
glycoscience papers 
published. The 25 top 
performing countries 
are depicted. 
This data was produced by carrying out a Web of Science literature search on 20th January 2015 using the following search terms: *glyco*, *glyco**genom*, *glycom* and *glyco**proteom* 
during 2010-2015 giving a total of 1,557,961 results. The EU produced 34.6% of the total search results versus the USA (30%), which had the 2nd highest country output [1].
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1. Walt et al. (2012) Transforming Glycoscience: A 
Roadmap for the Future, National Academies Press, 
Washington, D.C.
2. Glycobiology/Glycomics Market By Product [Enzymes 
(Glycosyltransferase, Neuraminidase, Glycosidase), 
Instruments (HPLC, Mass Spectrometry, MALDI-TOF), Kits, 
and Reagents], Application (Immunology, Oncology), End 
User Global Forecast to 2019, Markets and Markets
3. Pang et al. (2011) Science, 333, 1761 DOI: 10.1126/
science.1207438
The glycomics R&D market includes enzymes, instruments, 
kits, and reagents used in research and development. 
Glycomics is used in diagnostics, drug discovery research, 
immunology, oncology, and many other applications. The 
rapidly increasing global glycomics market (expected 
$930 million by 2019 from $510 million in 2014) is driven 
by investment in R&D from government and industry 
worldwide.  This strong investment is expected to drive 
current and future product development in glycoscience in 
areas such as Medicine, Biomaterials and Food [2]. 
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Glycomics R&D market sizes by geographical segment [2].
Carbohydrates such as starches have an essential role as a food 
source for animals and humans, and modern agrochemical 
biotechnologies are working to improve production yields of 
carbohydrates to ensure the stability of the food supply chain.
There is an increasing understanding that specific glycans can 
improve health and prevent disease. Carbohydrate polymers 
(oligo- and polyfructans, beta-glucans) can have a beneficial effect 
on human gut microbiota, and human milk oligosaccharides can 
help to improve long-term health. Glycans are also providing drug 
development targets and new druggable chemical entities.
European glycoscientists have been at the forefront of developing 
the novel tools needed for fast and reliable synthesis and analysis of 
glycans including chemical, enzymatic or microbial synthesis, high-
throughput automated analysis, development of glycan microarrays 
and the establishment of databases and modelling tools to enable 
advances in glycobiotechnology. 
This has been recognised by the European community leading to 
the establishment of networks such as the EGSF to address the 
need for cross-disciplinary integrated approaches and interactions 
with large international glycoscience networks, such as those 
established in the US, Japan or Canada [1]. At the same time there 
are a growing number of national glycoscience centres, large FP7 
and H2020 funded research and training programmes, COST 
programmes and training schools in Europe [see page 15]. In 2012 
the US National Research Council on behalf of all the National 
Academies published ‘Transforming Glycoscience: A Roadmap 
for the Future’ [1] in consultation with the international scientific 
community. This extensive review of the state-of-the-art highlighted 
the strength of glycoscience in many European countries. 
We see a number of exciting opportunities which are of great 
interest to European Bioindustries, such as:
• Developing cost-effective processes for using carbohydrate- 
 based feedstocks to produce existing and novel materials with  
 low carbon footprint, reducing reliance on fossil raw materials.
• Reducing healthcare costs by using carbohydrate-based   
 biomarkers to develop more effective disease diagnoses and  
 better targeted/personalised medicines.
• Developing new vaccines, antimicrobials, anticancer drugs and  
 diabetes treatments, and creating more efficient and cost-  
 effective production processes, by building on and underpinning  
 the recent successes of biopharmaceuticals. 
• Understanding more about glycans in foods (such as milk   
 oligosaccharides, soluble fibre, sweeteners) and their health   
 benefits; learning how they can contribute to prevention of   
 disease and overall wellbeing especially in infants and in old age,  
 for example through their interaction with the gut microbiota;  
 and improving large scale production processes.
You wouldn’t be here 
today without sugars! 
Human fertilization is 
mediated by a specific 
sugar sequence - sialyl-
LewisX (SLeX) identified 
by researchers at 
Imperial College 
London [3].
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Glossary
Carbohydrates are also known as sugars, saccharides and glycans.  
Glycoconjugates are biomolecules such as proteins, lipids or metabolites linked to glycans. 
Glycoscience and Glycobiotechnology encompass all activities related to the science and 
technology of carbohydrates, repectively. 
Glycomics studies the structure and function of carbohydrates in cells, tissue and organisms.
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Opportunities for trans-European 
collaborative projects
Biopharmaceuticals are generally expressed in plant or animal 
cell lines, or in microorganisms. A better understanding of the 
glycosylation processes in these expression systems would be of 
great benefit to the pharma and biotech industries [2].
As an example, there are around 500 genes involved in glycosylation 
in the cell. Knowledge about the way in which these interact allows 
glycosylation to be controlled. Glycoengineered cell lines are now 
The role of glycoscience in 
pharmaceuticals
The number of therapeutics based on glycans, glycan targets 
and glycosylated products is rapidly increasing. Examples 
including heparin, cyclodextrin, carbohydrate-based vaccines, and 
glycosylated natural products such as the antimicrobial vancomycin 
have been on the market for a long time. More recent examples 
include Tamiflu and Relenza, which were developed to treat the 
influenza virus. With the advent of biopharmaceuticals such as 
human erythropoietin and therapeutic antibodies, glycoconjugates 
will continue to increase their major market share.
Therapeutic glycoproteins: 
an important group of 
biopharmaceuticals
Approximately 40% of all approved therapeutic proteins and 
eight of the top ten selling biologics of 2010 [1] (generating over 
$35 billion in annual sales) contain N-linked oligosaccharides. 
Hence an understanding of the glycosylation of biologics is of 
paramount importance for the biopharmaceutical sector. The 
challenges in the development and production stages are to 
create a defined and targeted glycan profile, resulting in better in 
vivo product characteristics and increased biotherapeutic efficacy. 
Glycoengineering of host cell lines and process optimization to 
achieve higher efficacy and tight quality control of glycoprotein 
production will be paramount for current and future biologics.
Glycoengineering
The Novo Nordisk Foundation with assets from Novo Nordisk and 
Novozymes recently funded The Center for Biosustainability with 
a total of €150M of which approximately €35M is devoted to 
engineering the Chinese hamster ovary (CHO) cell line for improved 
production of therapeutics including genetic engineering of 
glycosylation capacities.
Tools
Glycosylated biopharmaceuticals such as glycoproteins provide 
particular challenges in terms of production and analysis for quality 
control (ICH guideline Q6B). Glycoproteins are generally produced 
via fermentation in cell lines. Whereas the sequences of the proteins 
are constant, the patterns of glycosylation on the molecule can 
be variable and may depend on the production conditions. This 
variability can influence the efficacy and safety of the resulting 
therapeutics.
There is a particular demand for tools that can address the 
following challenges:
• Working with patterns of glycosylation on recombinant   
 glycoproteins to manage safety and efficacy.
• Changing the glycome of cells, in particular stem cells, to   
 improve engraftment after transplantation or change   
 their capacity for immune response.
• High throughput analysis to provide benchmarking for drug   
 supply chain security and the development of novel glyco-drugs.
• Creating assays for glycan-mediated function such as targeting,  
 or changing the molecule’s half-life through glycosylation.
Addressing these challenges would be of great benefit to major 
European industries including biotech, pharma and biosimilar 
industries and instrument manufacturers, as well as the healthcare 
sector. Patients will also benefit through development of 
biopharmaceuticals that are lower cost, safer and more effective.
Heparin, a polysaccharide 
(1-5) that interacts with 
antithrombin (grey) in blood 
used to regulate clotting. 
European researchers are 
investigating heparin for 
the treatment of other 
diseases including cancer, 
inflammatory conditions, 
malaria, and amyloid 
diseases. With thanks to 
Prof Ulf Lindahl
Pharmaceuticals
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Top 10 best-selling drugs in 
Europe 2008–2013
Biologicals now dominate the top 10 list of best-selling 
medicines in Europe, with eight of the top 10 best-selling 
drugs now being biological (highlighted in green) [1]. 
Erythropoietin (EPO)
Perhaps one of the most well known examples of a 
biopharmaceutical is erythropoietin, also known as EPO. EPO 
is a glycoprotein with approximately 40% of its weight due to 
glycosylation [3]. Advances in recombinant DNA technology 
techniques have allowed the production of recombinant EPO 
for therapeutic use in treating anaemia, first approved by the 
FDA in 1989. Glycoscience has since played a major role in 
bringing improved EPO variants with modified glycosylation 
to the market. One such product Aranesp® from Amgen has 
been found to have a significantly longer half-life in the body 
after injection providing improved therapy. It is anticipated 
that worldwide sales of EPO therapeutic products will 
continue to grow as even more effective variants for anaemia 
treatment are found.
National Institute for Bioprocessing Research & 
Training (NIBRT), Dublin 
NIBRT is a world-class institute that provides research and 
training solutions for the bioprocessing industry. NIBRT 
houses the Glycobiology group headed by Professor Pauline 
Rudd, which performs research, analysis and training focused 
towards the needs of the Biopharmaceutical Industry.
Drug discovery and development represents a significant 
portion of the global R&D glycomics market, some 36.63% in 
2014. This segment is poised to reach $353.29 million by 2019 
from $187.69 million in 2014 [4].
Glycomimetics
Glycomimetics are small organic molecules derived from 
sugars. They have been shown to have activity both in 
vitro and in vivo with good safety profiles. They have very 
favourable attributes as drug molecules including water 
solubility, absorption, blood brain barrier penetration, 
chemical and biological stability, and oral bioavailability. This 
class of compounds provides the scientist with access to new 
polar chemical space for the development of therapeutics.
1. ‘Biologicals dominate Europe’s best sellers’ IMS Health, 
MIDAS, MAT June 2013
2. Shi and Goudar (2014) Biotechnology and 
Bioengineering, 111 (10) 1907 DOI: 10.1002/bit.25318
3. Bunn H.F. (2013) Cold Spring Harbour Perspectives in 
Medicine 3:a011619 DOI: 10.1101/cshperspect.a011619
4. Glycobiology/Glycomics Market By Product [Enzymes 
(Glycosyltransferase, Neuraminidase, Glycosidase), 
Instruments (HPLC, Mass Spectrometry, MALDI-TOF), Kits, 
and Reagents], Application (Immunology, Oncology), End 
User Global Forecast to 2019, Markets and Markets
2008 2013
1 Lipitor
(high cholesterol)
Humira 
(arthritis)
2 Seretide 
(asthma)
Seretide 
(asthma)
3 Plavix
(blood clotting)
Enbrel
(autoimmune diseases)
4 Herceptin
(breast cancer)
Herceptin
(breast cancer)
5 Enbrel
(autoimmune diseases)
Mabthera
(leukaemia)
6 Zyprexa
(schizophrenia and bipolar disorder)
Remicade
(arthritis)
7 Lovenox
(deep vein thrombosis)
Lovenox
(deep vein thrombosis)
8 Glivec
(cancer)
Avastin
(cancer)
9 Pantozol
(stomach acid)
Lucentis
(age-related macular degeneration)
10 Symbicort
(asthma and COPD)
Lyrica
(epilepsy)
available and high throughput analysis allows the products from 
these to be thoroughly characterised. This results in a much more 
homogenous product which may be more effective and will be easier 
to manage from a regulatory point of view. However, the development 
of more precision glycoproteomics tools are also required. 
Human erythropoietin - a 
glycoprotein. The glycans 
(red) are linked to the protein 
(blue) via individual amino 
acids (orange) that make 
up the protein polypeptide 
chain. With thanks to 
Professor Pauline Rudd.
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The role of glycoscience in 
personalised medicine
All cells, including human cells, have carbohydrates on their surface, 
in a covering known as the glycocalyx. This coating of glycolipids 
and glycoproteins controls a variety of fundamental biological 
processes, for example helping sperm to recognize eggs during 
fertilization, determining blood groups, or enabling the body to 
identify diseased cells or infectious agents. The carbohydrates of 
the glycocalyx are produced through highly complex biosynthetic 
pathways controlled by both genes and the environment. The 
makeup of the glycocalyx is therefore highly sensitive to genetic 
mutations, changes in gene activation or silencing, or environmental 
factors such as diet, alcohol consumption or smoking. This makes 
the glycocalyx a useful target for personalized medicine, including 
finding new biomarkers for diseases such as cancer, and for patient 
stratification in clinical trials.
Glycobiomarkers and disease 
intervention targets
Glycobiomarkers have potential in a number of diseases:
Infectious diseases:
Carbohydrates mediate many host-pathogen interactions, for 
example the flu virus recognises its host by binding to a particular 
sugar (sialic acid) on the cell surface. This sugar can be used as a 
target in diagnostics and therapeutics, such as Tamiflu or Relenza
Cancer:
Cell surface glycans on cancer cells are a rich source for biomarkers, 
and may be involved in metastasis 
Diabetes and associated diseases:
Glycosylation and glycation on cell surfaces can cause problems in 
diabetes, and have potential as biomarkers
Immune diseases:
Glycans act as targets for antibodies, which are also glycosylated proteins
Glycan databases and standards
Researchers seeking to understand the biochemical structure-
function relationships of carbohydrates require detailed descriptions 
of the assay conditions and the experimental results. While these 
are currently insufficiently reported in the literature, as glycoscience 
research advances, there will be increasing amounts of emerging 
scientific data. 
To manage the data, and to make the information accessible to 
the wider scientific community, publicly available databases and 
modelling tools have been developed for use in glycoscience. 
There are a number of challenges involved, however – finding a 
permanent home for these bioinformatics tools, and establishing 
standards to ensure the quality and consistency of the data (see 
textbox on MIRAGE). The MIRAGE project “Minimum Information 
Required for A Glycomics Experiment” is working to establish 
guidelines for data presentation from glycomics research in a variety 
of outputs including reporting experiments in scientific journals 
through to online database entries [2].
Why are Pandemic Seasonal and 
Bird Flu viruses different?
Many viruses attach to human cell surface sugars. Professor Ten 
Feizi’s research group at Imperial College London have used 
carbohydrate microarrays to understand this process and have 
uncovered how seasonal, pandemic 2009 swine flu and bird flu 
viruses differ in their cell surface recognition. [1]
The flu virus
Personalised 
Medicines
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Challenges and opportunities in 
personalised medicine
As personalised medicine advances, there will be many 
opportunities to develop lower-cost and better targeted products 
for the diagnostics market such as: on-/in-body sensors; 
nanotechnology-based sensors for use in the field; theranostics; 
companion diagnostics. 
An understanding of pharmacoglycomics and the opportunity to 
monitor human glycomes beyond blood group antigens will be 
an increasingly important aspect in personalised medicine and 
regenerative medicine. 
Development of fast and effective diagnostic tools for the detection 
of pathogens and for monitoring of health and disease will greatly 
benefit society by both reducing human suffering and cutting 
healthcare costs. The tools will also allow governments and 
healthcare providers to put preventative measures into place, for 
example vaccination programs in infectious disease outbreaks, or 
targeted interventions for diseases such as cancer or diabetes.
These new opportunities will be of great benefit to pharmaceutical, 
biotechnology and diagnostic companies and to the healthcare systems. 
1. Liu et al. (2009) J. Virol. 84, 12069-
12074 DOI: 10.1128/JVI.01639-10
2. http://www.beilstein-institut.de/en/
projects/mirage
3. Park et al. (2013) Chem Soc Rev., 42, 
4310-4326 DOI: 10.1039/C2CS35401B
4. http://glycobiom.eu
5. Thanabalasingham et al. (2013) 
Diabetes, 62(4), 1329-37. DOI: 10.2337/
db12-0880
6. Both et al. (2014) Nature Chemistry 6, 
65–74 doi:10.1038/nchem.1817
Glycan array technologies have become an important tool to 
study carbohydrate-protein interactions [6]
Studying glycan interactions to find biomarkers 
for disease
Glycans decorate cell surfaces in the form of glycoconjugates, 
where glycans are bound via proteins, ‘glycoproteins’ or 
lipids, ‘glycolipids’ to make up the glycocalyx. The glycocalyx 
can be mimicked in the laboratory using carbohydrate arrays 
where glycans are displayed on the surfaces of microarrays. 
Such ‘glycoarrays’ have been used to identify biomolecular 
interactions involved in signalling on cell surfaces [3].
Glycobiomarkers have enormous potential for use in 
diagnostics and personalised medicine. In the the EU project 
GlycoBioM - ‘Tools for the Detection of Novel Glyco-
biomarkers’ [4] high-throughput screening technologies 
have been used to identify new glycan biomarkers for a 
range of diseases. For example, the team have discovered a 
novel biomarker for maturity-onset diabetes of the young 
(MODY) [5].
Glycans in stem cells and regenerative medicine
European scientists have carried out significant research 
into the role of glycans in stem cells and the application of 
glycan-based technology for regenerative medicine and 
tissue engineering, such as materials for organ replacement 
and patient-specific testing of therapeutics. 
Glycans on the surface of cells re-organise as cells 
differentiate, producing tissue- and cell-type specific glycans, 
which determine stem cell fate. Glycans have also been 
found to be key molecules that direct cell behaviour making 
them excellent markers of stem cells, offering attractive 
targets for the specific delivery of therapeutics or toxins 
for cancer treatment or as tools to manipulate stem cell 
differentiation in vitro.
Stem cell therapies also have potential for treating Congenital 
Diseases of Glycosylation (CDGs) – hereditary diseases with 
impaired glycosylation processes, some of which are lethal.
Stem cells display a characteristic pattern of sugars (shown 
here in green) that direct their behaviour and can be used 
to target them in vivo. Image shows bone marrow-derived 
mesenchymal stem cells. Nuclei in blue, actin cytoskeleton in 
red and heparan sulphate glycosaminoglycans in green. With 
thanks to Dr Catherine Merry.
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Tools
The last 10 years has seen great advances in development of tools 
for glycan analysis. Examples include:
• Commercially-available LC/MS instrumentation and   
 workflows
• Glycan arrays for the identification of carbohydrate-  
 binding proteins
• Commercially-available anti-carbohydrate antibodies
• Virtual screening of carbohydrate specificity
• Diagnostic imaging using labelled carbohydrates in cells   
 and whole organisms
• 2D electrophoresis
• Lectin blotting
• Blood group screening
• Contrast agents
• Nanoparticles
• Glucose biosensors
• High-throughput genomic sequencing of genes involved in   
 carbohydrate biosynthesis
•	 Novel	synthetic	methods	for	the	production	of	glycan	standards
CASPER - an online tool for calculating NMR chemical shifts of oligo- and 
polysaccharides
http://www.casper.organ.su.se/casper/
CAZY – Carbohydrate Active Enzymes - describes the families of structurally-
related catalytic and carbohydrate binding modules (or functional domains) of 
enzymes that degrade, modify or create glycosidic bonds
http://www.cazy.org
Glycan Library – a list of approximately 830 lipid-linked sequence-defined 
glycan probes derived from diverse natural sources or chemically synthesised
https://glycosciences.med.ic.ac.uk/glycanLibraryIndex.html
GlycoBase 3.2 – a database of over 650 N- and O- linked glycan structures 
HPLC, UPLC, exoglycosidase sequencing and mass spectrometry (MALDI-MS, 
ESI-MS, ESI-MS/MS, LC-MS, LC-ESI-MS/MS) data 
https://glycobase.nibrt.ie/glycobase/show_nibrt.action
Glyco3D – a portal of 3D structures of mono, di, oligo and polysaccharides 
and carbohydrate recognizing proteins (lectin, monoclonal antibodies, 
glycosyltransferases and glycosaminoglycan binding proteins:  
http://www.glyco3d.cermav.cnrs.fr
Glycan Builder – a software library and set of tools to allow for the rapid 
drawing of glycan structures with support for all of the most common 
symbolic notation formats
http://www.unicarbkb.org/builder
GlycoDomainViewer – an online resource to study site glycosylation with 
respect to protein context and conservation
http://glycodomain.glycomics.ku.dk
GlyMAP – an online resource mapping out the variational landscape of 
glyco-active enzymes
http://glymap.glycomics.ku.dk
GlycoMod – an online tool to predict oligosaccharide structures on proteins 
from experimentally determined masses
http://web.expasy.org/glycomod/
GlycoMiner/GlycoPattern – software tools designed to detect, characterize 
and perform relative quantitation of N-glycopeptides based on LC-MS runs 
http://www.szki.ttk.mta.hu/ms/glycominer/
Glycosciences.de – a collection of databases and bioinformatics tools for 
glycobiology and glycomics
http://glycosciences.de/index.php
MonosaccharideDB – a comprehensive reference source for monosaccharide 
notation http://www.monosaccharidedb.org/start.action
NetOGlyc – next generation prediction of O-glycosylation sites on proteins  
http://cbs.dtu.dk/services/NetOGlyc/
SugarBind – a database of known carbohydrate sequences to which 
pathogenic organisms (bacteria, toxins and viruses) specifically adhere
http://sugarbind.expasy.org
SweetUnityMol – software to display 3-D structures of carbohydrates, 
polysaccharides and glycoconjugates
http://sourceforge.net/projects/unitymol/files/
UniCarbKB – online information storage and search platform for glycomics 
and glycobiology research
http://www.unicarbkb.org
UniProtKB – the universal protein sequence database with information on 
glycosylated proteins
http://www.uniprot.org/
A number of online databases and tools have been developed by European researchers and are now open access and valuable 
resource for the worldwide glycoscience community:
The GlycanBuilder software was developed 
as part of the EUROCarbDB project.
It provides the scientific community with an intuitive, 
interactive glycan drawing tool that is internationally 
used to present carbohydrates in different notation 
formats [1, 2].
Enabling 
Technologies 
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European glycoscientists are leading MIRAGE - a 
global effort to improve the quality of glycomics 
data in the literature.
The MIRAGE project “Minimum Information Required for A 
Glycomics Experiment” is funded and co-ordinated by the 
Beilstein Institute and is a global effort with representatives 
from Europe (UK, Germany, Ireland, Sweden) working 
together with counterparts from the USA, Australia, and 
Taiwan. Since 2011, the group has been working to establish 
guidelines for data presentation from glycomics research 
in a variety of outputs including reporting experiments 
in scientific journals through to online database entries 
[3]. It is expected that consistent reporting will allow clear 
communication of the wide range of glycoscience research 
efforts for the benefit of the broader scientific community. 
The MIRAGE working group reports the progress of its 
work at the Beilstein Glyco-Bioinformatics Symposia and in 
scientific journals. 
The MIRAGE project is an excellent example of how 
collaboration between European laboratories and beyond 
can make significant advances in glycoscience that would be 
impossible in single research centres or laboratories. [4]
European glycoscientists are at the 
forefront of developing novel tools 
for glycan synthesis
The glycan structures found in nature can 
be made in the laboratory using organic 
chemistry methods starting from and using 
carbohydrates. Termed ‘Glycomimetics’, as well 
as leads for drug development these can be 
used as chemical probes (to inhibit or stimulate 
activity) which are useful for understanding 
lectins and carbohydrate processing enzymes, 
to identify inhibitors/(ant)agonists/ligands, 
as biomarkers, or as diagnostic agents with 
huge potential in the development of novel 
vaccines, diagnostics and therapeutics against 
infectious diseases for application in health 
and medicine. Some bioactive oligosaccharides 
can be produced in large-scale quantities at 
low cost by bacterial fermentation.
Another approach to the synthesis of glycans 
is to use solid supports enabling the assembly 
of sugar building blocks into glycans, 
in a similar way to the programmable 
synthesisers that have long been used to 
produce DNA and amino acid sequences.
Research pioneered by Professor Peter 
Seeberger, (Director of the Max-Planck 
Institute for Colloids and Surfaces in Potsdam) 
[5] in this area has led to the first automated 
solid –phase carbohydrate synthesiser to 
be built which is currently being trialled by 
researchers at the University of Leiden and 
a second machine will be installed at the 
University of York  in 2015.
European Training Course on Carbohydrates - A four day course that 
takes place every two years at Wageningen University. This broad course in 
glycosciences combines general introductions in the field of polysaccharides 
and glycoproteins. http://www.vlaggraduateschool.nl/glycosciences/
Glycobiology & Glycochemistry e-learning course - A series of youtube 
videos and downloadable powerpoint presentations sponsored by the EGSF. 
http://www.egsf.org/resourcecentre/links/
GlycoPedia - A series of “eChapters” on selected important topics in 
glycoscience with the intention of promoting the field and providing material 
for educational purposes. http://www.glycopedia.eu
GlycoTRIC – Glycobiology Training, Research and Infrastructure Centre 
- A two week summer course that takes place annually at Imperial College 
London to promote interdisciplinary study of the functions of sugars in 
biology and their roles in human health. http://www3.imperial.ac.uk/glycotric
NIBRT - Provides classroom and laboratory courses on the subject of 
glycobiology and glycoanalytics, allowing students to gain a broad overview 
of the concepts, strategies and techniques that are used in research and 
biopharmaceutical analytical Glycoscience.
www.nibrt.ie or training@nibrt.ie
Training and education in glycosciences
Glycoscience is still an emerging technology, and so it will be important to educate the users of the technologies, which will include patients, healthcare 
professionals, scientists and policymakers, with coordinated programmes of online training as well as seminars, meetings and conferences. A number of 
very popular summer workshops exist already, but this activity needs to be expanded to audiences outside the specialist glycoscience community.
1. Ceroni et al. (2007) Source Code Biol Med. Aug 7;2:3. 
DOI: 10.1186/1751-0473-2-3
2. Damerell et al. (2012) Biol Chem. Nov; 393(11) 1357-62. 
DOI: 10.1515/hsz-2012-0135
3. York et al. (2014) Glycobiology 24(5):402–406.  
DOI: 10.1093/glycob/cwu018.
4. http://www.beilstein-institut.de/en/projects/mirage
5. Plante et al. (2001) Science, 291, 1523-1527. DOI: 
10.1126/science.1057324
6. Protein Engineering Market [Products (Monoclonal 
Antibody, Insulin Analog, Modified EPO), Technology 
(Sequential Modification, Glycosylation, PEGylation), and 
Applications (Therapeutics, Diagnostics, Research)] - Global 
Forecast to 2017, Markets and Markets
Training in Glycoscience is available in a number of formats:
Mass spectrometry is regarded as a gold standard glycomics 
technique and is expected to account for the largest share of 
the global glycomics instruments market - poised to reach 
$67.49 million by 2019 from $36.25 million in 2014 [6].
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There are a number of areas of 
opportunity:
Production of human milk oligosaccharides to promote  
infant health
Human milk oligosaccharides (HMOs) make up to 10% of solids 
in human milk, and provide many benefits in infant development 
and resistance to infection. Adding HMOs to formula milk could 
have potential to improve infant health, but HMOs are notoriously 
complex and challenging to produce and purify. There is therefore 
a need for alternative approaches, such as biotechnology routes 
including chemoenzymatic methods [1].
Milk Formula accounted for the largest share of the Overall 
Western Europe baby food and pediatric nutrition market 
– i.e. 44.48% – of Western Europe Baby Food & Pediatric 
Nutrition Market at $3,449.1M in 2012. The segment is 
expected to reach $3,977.7 M in 2017 [2]
Production of natural sweeteners
Sugar-based sweeteners are important components of food products. 
With the rise of obesity and diabetes in the world, there is a need to 
find lower calorie alternatives to sucrose, and these could be produced 
through biotechnology. A number of natural sweeteners, for example 
stevia, are carbohydrate-based. Larger-scale and lower-cost production 
through biotechnology could be an opportunity for the bioeconomy to 
provide society with healthier food.
Europe accounts for intense sweetener sales of €218M – an 
estimated 23% of the global market, with the region’s largest 
markets in the UK, France and Germany [3].
High intensity sweeteners & 
sugar substitutes
Due to rising rates of obesity and its associated diseases including 
diabetes, a number of alternatives to table sugar (sucrose) have 
been found and marketed for use as low-calorie alternatives for 
sweetening and enhancing the flavor of foods. High-intensity 
sweeteners are regulated as food additives [8]. Carbohydrate-based 
examples of sweeteners include sucralose (600 times sweeter than 
sucrose), steviol glycosides (>200 times sweeter than sucrose), Luo 
Han Guo fruit extracts (100 times sweeter than sucrose) as well as 
sugar substitutes such as sugar alcohols (includes xylitol often found 
in chewing gum) (>25% sweeter than sucrose) [8].
Did you know?
One litre of mature human milk contains about 5–15 g of free 
oligosaccharides, which is similar to the amount of protein 
present depending on the lactation period [7]. 
Glycobiology, food and health
Sugars are important components of everyday foods and an 
understanding of polysaccharide production in plants is important 
for food security and production, including crop protection.
The role of carbohydrates in foods as a way to improve health and 
prevent disease is increasingly discussed. As an example, prebiotic 
and antimicrobial oligosaccharides and polysaccharides have 
potential to treat and prevent infections, but further research is 
needed. As knowledge on the role of gut microbiota in health and 
functioning of humans and animals is vastly growing, the impact of 
food on the gut microbiota should be considered and the respective 
processes thoroughly studied.
Germination of barley. 
With thanks to Professor Rob Field.
Food and 
Nutrition 
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Prebiotics to promote health
Promoting a healthy gut microflora is increasingly understood to be 
important for infant and adult health and healthy aging, as well as 
preventing allergies, infection, immune disease and chronic disease. 
Prebiotics, usually carbohydrates such as galacto-oligosaccharides 
(GOS) prepared from cow milk lactose and fructo-oligosaccharides 
(FOS) prepared from plant inulins, support the growth of the 
gastrointestinal microflora, changing its composition or activity, and 
can improve wellbeing and health. 
The challenges are to identify prebiotic carbohydrates, study 
their interaction with the gut microbiota, and produce and purify 
them in sufficient quantities for the food industries either from 
natural sources (plants) or by enzymatic synthesis using sugar-
polymerizing enzymes and cheap sugars such as sucrose or lactose 
as the substrate. Such applications would need a much better 
understanding of the metabolic capabilities and functions of the gut 
microbiota. 
Maintaining a healthy gut flora using human milk oligosaccharides 
in infancy, and soluble fibre later in life, could be a cost-effective 
way to improve and maintain the health of our society.
The understanding of a healthy diet will need to go hand in 
hand with dialogues with regulatory bodies, education, public 
information, and marketing. Understanding the impact of food on 
human health would also have potential in veterinary markets.
By 2015, the European market for prebiotics in foods and 
beverages will reach €767 million [4].
Beneficiaries and end-users
Better understanding in this area will help to develop a more 
healthy society and facilitate considerable savings in healthcare 
costs. In addition, development of healthy food additives and 
substitutes is of great interest to the European food industries, 
drinks industries, and animal feed industries.
Beta-glucans – natural polysaccharides that are 
beneficial for health 
Beta-glucans are natural glucose polysaccharides that are 
found in many food sources including oats and other cereals, 
yeast and mushrooms and have been shown to be beneficial 
for health.
Beta-glucans have been shown to have cholesterol lowering 
properties and therefore can play an important role in reducing 
the risk of coronary heart disease. In 1991, the FDA approved the 
health claim and recommended a minimum of 3g per day. It has 
since been shown that increased consumption of beta-glucans 
leads to a corresponding decrease in the risk of coronary heart 
disease. 
Beta-glucans have also been found to have a beneficial 
impact on the immune system. They can bind to white blood 
cells and activate them leading to increased anti-tumour 
and antimicrobial activity. This understanding will help the 
pharmaceutical and health industries design new treatments 
and drugs based on beta-glucans [5,6].
1. Bode L. (2012) Glycobiology. 22(9):1147-62 DOI: 
10.1093/glycob/cws074
2. Western Europe Baby Food & Pediatric Nutrition Market: 
Analysis & Forecast (2007 - 2017) Research and Markets, 
Report ID: 1992059
3. European sweetener success is skewed to the West 
MARKET TRENDS
4. Prebiotic Ingredients (FOS, GOS, MOS, Inulin) Market for 
Food & Beverage, Dietary Supplements & Animal Feed – 
Global Industry Analysis, Size, Share, Trends, and Forecast, 
2012 – 2018, Transparency Market Research
5. Othman et al (2011) Nutrition Reviews Vol. 69(6):299–
309 DOI: 10.1111/j.1753-4887.2011.00401.x.
6. Brown et al (2001) Nature 413, 36-37 
DOI:10.1038/35092620
7. Han et al. (2011) Biotechnology Advances, 30(6), 1268-
1278 DOI:10.1016/j.biotechadv.2011.11.003
8. http://www.fda.gov/Food/IngredientsPackagingLabeling/
FoodAdditivesIngredients/ucm397716.htm
Colorimetric detection of the hydrolysis activity of various 
CGTase mutants – an enzyme used for modifying starch. 
With thanks to Centre de Researches sur les Macromolécules 
Végétales (Cermav), CNRS.
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Polysaccharides for sustainable 
materials 
The development of sustainable biorenewables will facilitate the 
move from our dependence on hydrocarbons towards a sustainable 
biobased chemicals industry with a lower carbon footprint. For 
example, cellulose, hemicellulose, starch, chitin, xyloglucan and 
other polysaccharides are all natural products and are often found 
in biological waste streams. They can be produced in plants that can 
be grown on low value or marginal land or even by bioremediation. 
Glycobiotechnology will have an important role in supporting 
the development of sustainable processes for the bioconversion 
and bioengineering of carbohydrates, to create tailor-made 
carbohydrate polymers with unique properties and for novel 
applications. There are many opportunities for innovation in the 
use of plant-derived oligo- and polysaccharides as performance 
chemicals, for example by modifying their polarity or functionality.
The self-organization of polysaccharides into dynamic and 
hierarchical supramolecular structures is a key characteristic of 
both plant (for example starch) and mammalian (for example 
hyaluronic acid) polysaccharides. Soft structures made of flexible 
polysaccharides are fundamental to the extracellular matrix and the 
nuclear pore permeability barrier. 
As in plants and mammals, polysaccharides are also present in 
bacteria and marine organisms such as algae. Investigations into 
polysaccharide biosynthesis in these organisms will no doubt reveal 
a range of useful enzymes for the production of biobased materials 
due to the vast diversity of microorganisms and their metabolic 
potential. These microbial enzymes can be used to convert 
carbohydrates on an industrial scale, and carbohydrate polymers 
with unique properties could be tailor-made.
These biorenewable materials have potential to replace 
petrochemical-derived soluble polymers for a variety of applications, 
including: Dispersants: pigment dispersion in paints; highly 
concentrated filler dispersions for paper; improved performance of 
detergents; cement dispersions fluidizing concrete for construction 
of high-rise buildings; Rheology modifier: increasing or decreasing 
viscosity for applications as diverse as shampoo formulation or 
enhanced oil recovery; Flocculants: contaminated water treatment.
Emerging tools
The synthesis and selective modification of polysaccharides is highly 
challenging. At production scale, ‘glycoenzymes’ that can catalyse 
the selective synthesis and modification of polysaccharides remain 
the most cost-effective and environmentally-friendly route. As more 
and more genomes are sequenced, novel glycoenzymes, particularly 
from microorganisms that use polysaccharides as feedstock, are 
now widely accessible and will transform glycobiotechnology.
Analytical methods based on nuclear magnetic resonance 
spectroscopy and mass spectrometry, together with atomic force 
microscopy, and optical tweezers are now used hand-in-hand with 
theoretical tools to analyse structures. New instrumentation is 
required to accompany the overarching concepts which are at the 
interface between physics and biology, to support the generation of 
highly-defined innovative biobased materials. 
Challenges and opportunities
Surprisingly little is known about polysaccharide biosynthesis 
and a complete understanding of the enzymes involved will help 
create improved production processes and novel biomaterials. For 
example, understanding the biosynthesis of cellulose [1], or learning 
more about the physical interactions within cell walls in order to 
overcome the barrier of cell wall degradation. Such key questions 
that could be addressed by large transnational and interdisciplinary 
European-based projects, the success of which will be of great 
benefit to the European bioeconomy. 
Building on past successes, the use of enzymes in biotechnology 
in combination with chemical synthesis is expected to increase to 
create new high-value/low volume and low-value/high volume 
materials. 
As the next generation of advanced biorefineries are designed, 
it will be important to develop high-value carbohydrate-derived 
product streams of biomimetic and smart materials alongside with 
biodiesel and bioethanol to exploit the full commercial potential 
of biomass. Potential products include novel barrier coatings and 
membranes, natural emulsifiers, superabsorbers, fillers for wound 
healing, gelling agents and soft biomaterials for food science and 
biomedicine (e.g. tissue engineering) bioplastics, replacements for 
bisphenol A for (plastics), and drug delivery agents.
Images taken from reference 4.
Materials and 
Biorenewables
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A spotlight on cellulose-based biopolymers 
Cellulose is the most abundant natural polymer on earth. 
It is a linear, homo-polymer made up of glucose sub-units. 
Predominantly found in plants, cellulose is a crucial component 
of cell walls providing backbone and giving structure to plants. 
It is insoluble in water and biodegradable and it is a combination 
of all these properties that have made cellulose attractive for 
commercial exploitation as a biobased polymer.
The earliest examples of cellulose-based materials include 
cellophane (regenerated cellulose), nitrocellulose (cellulose 
treated with nitric acid) and celluloid (a mixture of 
nitrocellulose and camphor), which were discovered and 
developed in the late 19th and early 20th centuries.
Since then, various modifications of the –OH groups on the 
surface of cellulose has led to a wider range of cellulose 
materials being made available. These cellulose derivatives 
are mainly cellulose esters and cellulose ethers which have 
various properties that has enabled their use in a wide range 
of applications from plastics in coatings, inks, gelling and 
thickening agents, adhesive and binders and more. 
As well as chemical modification of cellulose, the 
polymer can be broken down into smaller fragments for 
example into nanocellulose, which has been reported as 
a useful reinforcing agent in composite materials termed 
‘nanocomposites’ [2].
These modifications of cellulose are mostly carried out 
using traditional chemical methods, however, enzymes are 
increasingly being used in a more sustainable approach 
to the production of cellulose-based biopolymers, as well 
as other sugar-based polymers including starch. A greater 
understanding of the production of cellulose in plants 
would allow even more possibilities for cellulose-based 
biopolymers. 
Cellulose and Starch  - natural examples of how the structure 
of a polysaccharide can affect its properties and uses
Cellulose and starch are both naturally occurring homo-
polymers of glucose. However, both polysaccharides have 
different structures and have different roles in nature.
In cellulose, the glucose sub-units are linked in straight 
chains via β-1-4 linkages and provides structure to plants. In 
starch, the glucose sub-units are found in two forms; amylose 
(straight chains of glucose linked with α 1-4 linkages) and 
amylopectin (branched chains of glucose with α 1-4 linkages 
and α 1-6 linkages) and is used as an energy store [3, 4].
End-users
Major beneficiaries will include a wide and diverse 
range of companies involved in the bioeconomy of 
Europe: 
• Chemical industries
• Energy companies developing advanced  
 biorefineries
• Medical device companies for novel biomaterials
• Membrane companies
• Biotechnology companies
• Healthcare sector
• Food ingredients
• Packaging
• Biodegradable materials (e.g. for nappies)
• Cosmetic companies
1. Chauve et al. (2013) Advances in Bioscience and 
Biotechnology, 4, 1095-1109 ABB DOI: 10.4236/
abb.2013.412146
2. Pullawan et al. (2014) Carbohydrate Polymers 100 
31–39 DOI:10.1016/j.carbpol.2012.12.066
3. Perez, S. and Bertoft, E. (2010) Starch 62, 389–420 DOI: 
10.1002/star.201000013
4. Perez et al. (2010) Adv. in carbohydrate chemistry 
and biochemistry 64, 25-116 DOI:10.1016/S0065-
2318(10)64003-6
5. Atanassov et al. (2009) J. Biol. Chem., 284, 3833-3841 
DOI: 10.1074/jbc.M807456200
6. http://ec.europa.eu/research/bioeconomy/h2020/bio-
based-industries_en.htm
We encounter cellulose in our everyday lives in the form of 
cotton, paper and wood products. Europe has a strong history 
in the paper and pulp industry with some of the largest 
producers in the world located in northern Europe where 
they can take advantage of the ready supplies of the wood 
required produced in the Scandinavian forests. However, 
with more and more print moving online, the demand for 
paper products is dwindling. Technologically, the processing 
of wood for pulp and paper may not differ much from that 
required to process biomass into sustainable materials and 
chemicals. This pre-existing infrastructure will play a vital 
role in bringing newly developed sustainable products to 
market in Europe and beyond.
Estimates conclude that a shift to biological raw materials 
and biological processing methods could save up to 2.5 billion 
tons of CO2 equivalent per year by 2030, increasing markets 
for bio-based raw materials and new consumer products 
several-fold [6].
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About the ESF
The European Science Foundation (ESF) is an independent, non-
governmental organisation, the members of which are 66 national 
funding agencies, research performing agencies and academies 
from 29 countries. 
The strength of ESF lies in its influential membership and in its 
ability to bring together the different domains of European science 
in order to meet the challenges of the future. 
Since its establishment in 1974, ESF, which has its headquarters in 
Strasbourg with offices in Brussels and Ostend, has assembled a 
host of organisations that span all disciplines of science, to create a 
common platform for cross-border cooperation in Europe. 
ESF is dedicated to promoting collaboration in scientific research 
and in funding of research and science policy across Europe. 
Through its activities and instruments, ESF has made major 
contributions to science in a global context. ESF covers the 
following scientific domains:
•  Humanities
•  Life, Earth and Environmental Sciences
•  Medical Sciences
•  Physical and Engineering Sciences
•  Social Sciences
•  Marine Sciences 
•  Materials Science and Engineering
•  Nuclear Physics
•  Polar Sciences
•  Radio Astronomy
•  Space Sciences
About IBCarb
IBCarb – Glycoscience Tools for Biotechnology and Bioenergy is a 
BBSRC funded Network in Industrial Biotechnology & Bioenergy. 
IBCarb will support UK glycoscientists to develop cutting edge 
technology in synthesis, biology and analysis of carbohydrates and 
bring these technologies to the market and provide innovative 
manufacturing processes. Glycoscience has clear strategic relevance 
to both industrial biotechnology and bioenergy and IBCarb with 
its focus on natural carbohydrates is ideally placed to contribute 
to many aspects of the Industrial Biotechnology and Bioenergy 
agenda, moving away from dependence on hydrocarbons to 
develop sustainable biotechnologies and reduce green house gas 
emissions and ensuring both energy and food security. 
IBCarb activities are organized around 5 themes:
• Tools
• Renewables (Materials, Chemicals & Energy)
• Food
• Health
• Societal Impact
www.ibcarb.com
Please reference as – Flitsch et al. (2015) A roadmap for Glycoscience in Europe - a joint EGSF/IBCarb publication.
For more information about this White Paper please contact ibcarb@manchester.ac.uk
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nl || Biotechnology and Biosciences Department, Milano-Bicocca http://www.unimib.
it/go/888888907/Home/Italiano/Elenco-Docenti/NICOTRA-FRANCESCO-dipartimento-
di-biotecnologie-e-bioscienze || Carbohydrate Chemistry - Center of Chemistry and 
Biochemistry http://cqb.fc.ul.pt/research/carbohydrate-chemistry/ || Carbohydrate 
Competence Centre, http://www.cccresearch.nl/en/ || Carbohydrate Microarray Facility at 
Imperial College http://www1.imperial.ac.uk/glycosciences/ || Centre de Researches sur 
les Macromolécules Végétales (Cermav), CNRS http://www.cermav.cnrs.fr/en/user/1407 
|| http://chemicalsciences.unina.it/documents/research-groups/itemlist/category/10-sccn-
structure-and-synthesis-of-carbohydrates-naples || Chemistry for Life Sciences, University 
of Milan http://eng.chimica.unimi.it/ecm/home/research/themes-and-lines-of-research/
chimica-per-le-life-sciences || Copenhagen Center for Glycomics http://glycomics.ku.dk || 
Cyclolab http://www.cyclolab.hu || Department of Carbohydrates and Cereals http://sch.
vscht.cz/wp/ || Department of Structure and Function of Saccharides, Slovak Academy of 
Sciences http://www.modlab.chem.sk/home/projects/projects.html || Faculty of Pharmacy 
and Biochemistry, University of Zagreb http://lauc.pharma.hr || Finnish Glycoscience 
Graduate School http://www.hi.helsinki.fi/ggs/english/ || Glycobiology Division, Vienna 
Glycobiology, https://www.chemie.boku.ac.at/en/abteilung-fuer-biochemie-dchbc/
glykobiologie-gruppe/  || Glycosciences Laboratory http://www1.imperial.ac.uk/
glycosciences/ || GlycoTRIC http://www3.imperial.ac.uk/glycotric || GOTGLY http://www.
biomedicine.gu.se/biomedicine/research/niclas-karlsson/gothenburg-glycosciences/ || 
Institute of Microbiology, ETH-Zurich http://www.micro.biol.ethz.ch/research/aebi/maebi || 
Laboratory of Fungal Glycobiology http://www.ibb.waw.pl/en/structure/ibb-departments/
laboratory-fungal-glycobiology || Max Planck Institute of Colloids and Interfaces http://
www.mpikg.mpg.de/en/bs || Molecular Glycobiology, BOKU http://www.chemie.boku.
ac.at/abteilung-fuer-biochemie-dchbc/glykobiologie-gruppe/gruppe-wilson/?&L=1 || 
National Institute for Bioprocessing Research and Training (NIBRT) http://www.nibrt.ie || 
Norwegian Biopolymer Laboratory, NTNU http://www.biotech.ntnu.no/nobipol/index.php 
|| Oxford Glycobiology Institute http://www.bioch.ox.ac.uk/glycob/ || SIB Swiss Institute of 
Bioinformatics http://www.isb-sib.ch || York Structural Biology Laboratory http://www.york.
ac.uk/chemistry/research/ysbl/
Networks & Societies: Dutch Society for Glycobiology www.glycobiology.nl || EGSF – ESF 
Euroglycoforum Research Network Program http://www.egsf.org || Glycoscience Ireland 
www.glycoscienceireland.ie || IBCarb– Glycoscience Tools for Biotechnology & Bioenergy, 
a BBSRC NIBB, UK http://ibcarb.com || Royal Society of Chemistry Carbohydrate Group 
http://www.rsc.org/membership/networking/interestgroups/carbohydrate/
Projects: Amylomics - AmyloEnzymes Captured by Targeted Metagenomics, www.
amylomics.org || Carmusys – Carbohydrate Multivalent System as Tools to Study Pathogen 
Interactions with DC-SIGN www.carmusys.iiq.csic.es || Doctoral Program for the Chemistry 
and Chemical Biology of Carbohydrates and Heterocycles, University of Debrecen http://
www.chem.science.unideb.hu/Dprog_K5_en.html || Gastric Glyco Explorer: Systems 
glycobiology of gastric cancer http://www.isb-sib.ch/research/projects/systems-biology.
html#gastricglycoexplorer-systems-biology || GlycoBioM – Tools for the detection of 
novel glyco-biomarkers http://glycobiom.eu || GlycoHIT – Glycomics by High throughput 
Integrated Technologies http://www.glycohit.eu || GlycoPar – Parasite Glycobiology and 
anti-parasitic strategies http://www.glycopar.eu || Glycopharm – The sugar code from 
bio(chemical) concept to clinincs http://www.glycopharm.eu || HighGlycan – Methods 
for high-throughput (HTP) analysis of protein glycosylation http://www.highglycan.eu || 
IMMUNOSHAPE – “Development of Selective Carbohydrate Immunomodulators Targeting 
C-type Lectin Receptors on Antigen Presenting Cells” (ITN-ETN)  || Novosides - Novel 
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